Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biovaxys Technology Corp (BIOV.CN)

Biovaxys Technology Corp (BIOV.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,288
  • Shares Outstanding, K 291,525
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,955 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 06/30/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0200 +25.00%
on 07/18/25
0.0400 -37.50%
on 07/08/25
-0.0100 (-28.57%)
since 06/18/25
3-Month
0.0200 +25.00%
on 07/18/25
0.0500 -50.00%
on 04/21/25
-0.0250 (-50.00%)
since 04/17/25
52-Week
0.0200 +25.00%
on 07/18/25
0.0800 -68.75%
on 11/05/24
-0.0300 (-54.55%)
since 07/18/24

Most Recent Stories

More News
BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an extension of its previously announced brokered private...

BIOV.CN : 0.0250 (unch)
BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces it has engaged Enclave Capital LLC ("Enclave") to act as an...

BIOV.CN : 0.0250 (unch)
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its brokered private...

BIOV.CN : 0.0250 (unch)
Stocks in play: BioVaxys Technology Corp

Provides a summary of current operating initiatives including the integration and disposition of assets ...

BIOV.CN : 0.0250 (unch)
BioVaxys Issues Corporate Update

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives...

BIOV.CN : 0.0250 (unch)
Stocks in play: BioVaxys Technology Corp

Announces that the Company and Horizon Technology Finance Corporation have executed a follow-on Amendment ...

BIOV.CN : 0.0250 (unch)
BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces a proposed consolidation of the common shares of the Company...

BIOV.CN : 0.0250 (unch)
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")

/CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology...

BIOV.CN : 0.0250 (unch)
Stocks in play: BioVaxys Technology Corp

Announces today they have entered into a Research Agreement to collaborate on the development of new ...

BIOV.CN : 0.0250 (unch)
New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – Baystreet.ca News Commentary – Innovation in biotech is rapidly reshaping how we fight cancer, a trend reflected in the upcoming European...

PYXS : 1.1300 (-3.42%)
BVAXF : 0.0182 (-0.55%)
BIOV.CN : 0.0250 (unch)
SONA.CN : 0.6700 (+3.08%)
GRAL : 35.19 (-2.03%)
SNANF : 0.4884 (-0.08%)
ADPT : 10.39 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization,...

See More

Key Turning Points

3rd Resistance Point 0.0317
2nd Resistance Point 0.0283
1st Resistance Point 0.0267
Last Price 0.0250
1st Support Level 0.0217
2nd Support Level 0.0183
3rd Support Level 0.0167

See More

52-Week High 0.0800
Fibonacci 61.8% 0.0571
Fibonacci 50% 0.0500
Fibonacci 38.2% 0.0429
Last Price 0.0250
52-Week Low 0.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar